| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2023―Nov―23 |
COVID-19 cooling: Nanostrategies targeting cytokine storm for controlling severe and critical symptoms |
Yu Zheng, Yuke Li, Mao Li, Rujing Wang, Yuhong Jiang, Mengnan Zhao, et al. (+4) Jun Lu, Rui Li, Xiaofang Li, Sanjun Shi |
| 2 |
[GO] |
2023―Mrz―23 |
Use of baricitinib in treatment of COVID-19: a systematic review |
Ananyan Sampath, Aditya Banerjee, Shubham Atal, Ratinder Jhaj |
| 3 |
[GO] |
2023―Mrz―16 |
Research progress in spike mutations of SARS-CoV-2 variants and vaccine development |
Xuemei He, Cai He, Weiqi Hong, Jingyun Yang, Xiawei Wei |
| 4 |
[GO] |
2022―Jun―28 |
Enzymes in the time of COVID-19: An overview about the effects in the human body, enzyme market, and perspectives for new drugs |
Luana Xavier Soares Gomes Moura Fé, Eliane Pereira Cipolatti, Martina Costa Cerqueira Pinto, Suema Branco, Fábio César Sousa Nogueira, Gisela Maria Dellamora Ortiz, et al. (+2) Anderson de Sá Pinheiro, Evelin Andrade Manoel |
| 5 |
[GO] |
2021―Okt―26 |
Haste makes waste: A critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition |
Guillem Macip, Pol Garcia-Segura, Júlia Mestres-Truyol, Bryan Saldivar-Espinoza, María José Ojeda-Montes, Aleix Gimeno, et al. (+3) Adrià Cereto-Massagué, Santiago Garcia-Vallvé, Gerard Pujadas |
| 6 |
[GO] |
2021―Jan―18 |
What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design |
Muya Xiong, Haixia Su, Wenfeng Zhao, Hang Xie, Qiang Shao, Yechun Xu |
| 7 |
[GO] |
2021―Jan―04 |
Therapeutic targets and potential agents for the treatment of COVID-19 |
Yinuo Wu, Zhe Li, Yun-Song Zhao, Yi-You Huang, Mei-Yan Jiang, Hai-Bin Luo |
| 8 |
[GO] |
2020―Dez―05 |
Drug repurposing approach to combating coronavirus: Potential drugs and drug targets |
Jimin Xu, Yu Xue, Richard Zhou, Pei-Yong Shi, Hongmin Li, Jia Zhou |
| 9 |
[GO] |
2020―Nov―13 |
SARS-CoV-2-mediated immune system activation and potential application in immunotherapy |
Yuan Tan, Faqin Tang |
| 10 |
[GO] |
2020―Sep―02 |
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective |
Thanigaimalai Pillaiyar, Lukas L. Wendt, Manoj Manickam, Maheswaran Easwaran |
| 11 |
[GO] |
2020―Aug―31 |
COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays |
Xueqing Wang, Yuanfang Guan |
|
